SAN DIEGO, Nov. 4, 2015 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR); (TSX:TLB) ("TearLab" or the "Company") announced today that it will participate in two investor conferences in November.
-
On November 10th, TearLab will participate in the 2015 Stephens Fall Investment Conference at the New York Palace Hotel in New York City.
-
On November 19th, TearLab will present at the Canaccord Genuity Medical Technology & Diagnostics Forum 2015 at the Westin Grand Central Hotel in New York City. The presentation will begin at 3:00 PM Eastern Time. The presentation will be webcast live and archived for at least 90 days on the Company's website at http://www.tearlab.com under the "Webcasts" tab in the Investors section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity® Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning our future financial performance, the future success and performance of our principal product and the future status of reimbursement for our technology. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed with the SEC on August 7, 2015. We do not undertake to update any forward-looking statements.
CONTACT: Stephen Kilmer
(647) 872-4849
skilmer@tearlab.com
